Discovery and Characterization of a Potent and Selective Oral Inhibitor of STAT6 for the Treatment of Allergic Diseases 2257118
STAT6 is a transcription factor downstream of IL-4 and IL-13 signaling that acts as a key driver of type 2 inflammation, which is associated with atopic dermatitis and asthma. Inhibition of the IL-4/IL-13 pathway is clinically validated for treatment of allergic diseases. Our aim is to develop an oral small molec...